US FDA Amps Up "Name And Shame" Approach To Thwart Anti-Generic Tactics
Executive Summary
New draft guidance says citizen petition abuses will be referred to FTC and publicly called out as attempts to delay ANDA approvals.
You may also be interested in...
FDA Slams Citizen Petition: Harsh Language, FTC Referral Suggest Tougher Stance On ANDA Delay Tactics
While the FTC referral is not unique, this seems the first time US FDA has cited intent to delay generic approval as a ground for denying a citizen petition. With Califf's confirmation hearing suggesting some bipartisan consensus on the issue, FDA might soon find itself with new powers.
FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses
US FDA draft guidance on citizen petitions elicits comments of support, including call to exclude brand manufacturer petitions except in urgent situations.
FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses
US FDA draft guidance on citizen petitions elicits comments of support, including call to exclude brand manufacturer petitions except in urgent situations.